Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis

doi:10.4251/wjgo.v17.i9.109949

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 9

This Article

(44)

(46)

(0)

(745)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Sep 15, 2025; 17(9): 109949
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.109949

Full Size Figure Download Figure

Figure 2 Progression-free survival sensitivity analysis. A: After propensity score matching (PSM) analysis of progression-free survival (PFS) (ratio = 1); B: After PSM analysis of PFS (ratio = 2); C: After PSM analysis in PFS (ratio = 3); D: After PSM analysis of PFS (ratio = 4). SOC: Standard-of-care; CIT: Chemoimmunotherapy.

Citation: Gao Z, Zhou ZF, Wang XY, Song T, Wu SK, Jin X. Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis. World J Gastrointest Oncol 2025; 17(9): 109949
URL: https://www.wjgnet.com/1948-5204/full/v17/i9/109949.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i9.109949

Gao Z, Zhou ZF, Wang XY, Song T, Wu SK, Jin X. Chemotherapy plus bevacizumab vs chemoimmunotherapy for metastatic colorectal cancer: Real-world analysis. World J Gastrointest Oncol 2025; 17(9): 109949 [PMID: 40977666 DOI: 10.4251/wjgo.v17.i9.109949]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.